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Abstract
Background:  In daily clinical practice of a dental department it's common to find gingival
overgrowth (GO) in periodontal patients under treatment with Cyclosporine A (CsA). The
pathogenesis of GO and the mechanism of action of Azithromycin (AZM) are unclear. A systematic
review was conducted in order to evaluate the efficacy of Azithromycin in patients with gingival
overgrowth induced by assumption of Cyclosporine A.
Methods: A bibliographic search was performed using the online databases MEDLINE, EMBASE
and Cochrane Central of Register Controlled Trials (CENTRAL) in the time period between 1966
and September 2008.
Results: The literature search retrieved 24 articles; only 5 were Randomised Controlled Trials
(RCTs), published in English, fulfilled the inclusion criteria. A great heterogeneity between
proposed treatments and outcomes was found, and this did not allow to conduct a quantitative
meta-analysis. The systematic review revealed that a 5-day course of Azithromycin with Scaling and
Root Planing reduces the degree of gingival overgrowth, while a 7-day course of metronidazole is
only effective on concomitant bacterial over-infection.
Conclusion: Few RCTs on the efficacy of systemic antibiotic therapy in case of GO were found
in the literature review. A systemic antibiotic therapy without plaque and calculus removal is not
able to reduce gingival overgrowth. The great heterogeneity of diagnostic data and outcomes is due
to the lack of precise diagnostic methods and protocols about GO. Future studies need to improve
both diagnostic methods and tools and adequate classification aimed to determine a correct
prognosis and an appropriate therapy for gingival overgrowth.
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Background
Gingival overgrowth (GO) and gingival enlargement (GE)
are terms used to indicate a pathologic increased volume
of the gingiva instead of "hyperplasia" and "hypertrophy"
[1], previously adopted.
Currently there are more than 20 pharmacological formu-
lation that could be considered associated with GO [2-4].
These drugs can be divided into 3 categories: Calcium-
channel blockers [5-8], anticonvulsants [9,10], immuno-
suppressants [11-16]. They all recognize gingival connec-
tive tissue as secondary target tissue. Reliable figures of
prevalence of GO for these 3 different categories are not
available in literature: table 1 shows the results of main
epidemiological studies conducted in the USA.
Drug-induced GO has a multifactorial etiology [17]. The
effects of the pharmacological molecules are modulated
by these factors: plaque index [18] (directly correlated);
gender (males are three times more sensitive); age
(inversely correlated); drug's daily dose (directly corre-
lated); HLAB37 positivity and simultaneous administra-
tion of corticosteroids or one of the 2 other categories
[19]. All these factors act in various means synergistically
enhancing GO [20]. The pathogenetic mechanism of
drug-induced GO is still unclear. It's modulated by fibrob-
lasts [21,22], cytokines [23-25], matrix metalloprotein-
ases [26].
They seem to interact in a complex network to create the
typical histopathological lesion of GO: an increased vol-
ume of the gingiva due to an abnormal stroma of connec-
tive tissue with overproduction of collagen and other
extracellular matrix proteins, infiltrated by plasmacells
and covered by parakeratinized epithelium also project-
ing irregular epithelial ridges deep inside [27].
In daily clinical practice of a dental department it's com-
mon to find GO in periodontal patients under treatment
with Cyclosporine A (CsA), for example in transplanted
subjects [28-32].
In our study a systematic review was conducted with the
aim of evaluating the efficacy of Azithromycin (AZM) in
patients with GO induced by assumption of Cyclosporine
A (CsA).
The review question was:
- how effective is AZM in terms of clinical outcomes in
patients with GO induced by assumption of CsA?
Table 1: Estimated prevalence of Drug-Associated Gingival Enlargement according to the most frequently reported prevalence rates 
(Informational Paper: Drug-Associated Gingival Enlargement. J periodontal 2004;75:1424–1431)
Category Pharmacologic Agent Trade Name Prevalence
Anticonvulsants Phenytoin Dilantin 50%
Sodium valproate (valproic acid) Depakene, Depacon, Epilim, Valpro Rare
Phenobarbitone Phenobarbital, Donnatal <5%
Vigabatrin Sabril Rare
Carbamazepine Tegretol None reported
Immunosuppressants Cyclosporin Neoral, Sandimmune Adults 25–30%
Children >70%
Calcium channel blockers Nifedipine Adalat, Nifecard, Procardia, Tenif 6–15%
Isradipine DynaCirc None reported
Felodipine Agon, Felodur, Lexxel, Plendil Rare
Amlodipine Lotrel, Norvasc Rare
Verapamil Calan, Covera, Isoptin, Tarka, Verelan <5%
Diltiazem Cardizem, Dilacor, Diltiamax, Tiazac 5–20%BMC Oral Health 2008, 8:34 http://www.biomedcentral.com/1472-6831/8/34
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Methods
In accordance with Needleman [33], a protocol was devel-
oped and it included all aspects of the review methods:
inclusion criteria for studies, search strategy, screening
methods, data abstraction, quality assessment by two
independent reviewers and data synthesis.
Inclusion criteria
Type of studies
Only Randomised Controlled Trials (RCTs) or systematic
reviews were included because the RCT is the most appro-
priate design to choose for reviews of effectiveness of ther-
apy.
Subjects
Only patients with a clinical diagnosis of GO induced by
assumption of Cyclosporine A (CsA).
Type of treatment intervention: the intervention of inter-
est is the use of Azithromycin (AZM) with and without
scaling root planing (SRP); while the control groups
received other systemic or local antimicrobials or placebo
with and without SRP.
Types of outcome measures
Main change in clinical attachment level (CAL), mean
change in probing pocket depths (PPD), changes in bleed-
ing on probing (BOP), gingival index (GI) and plaque
index (PI), changes in coronal tooth length or clinical
crown length and in distance between interdental papilla
and CEJ (cementum-enamel junction) were reported in
this review as outcome measures.
Search strategy
A research was performed using these online databases:
MEDLINE (from 1966 to September 2008) Cochrane
Oral Health Group Trials Register (September 2008);
Embase (from 1988 to September 2008). The search strat-
egy was as follows: our review question was divided in its
main components to develop correct search terms for the
databases, establishing a hierarchical order and using
"text" terms, adopted by authors in the title and abstract,
and code terms, adopted by the indexer of the database;
the resulting key-words were: gingival overgrowth,
Cyclosporine A, Azithromycin.
Then the search using key-words was performed into 2
different ways, using Boolean operators: "(gingival over-
growth OR GO OR gingival enlargement) AND
(Cyclosporine OR Cyclosporine A OR CsA) AND (Azi-
thromycin OR AZM OR AZT)" and without using Boolean
operators: "gingival overgrowth CsA Azithromycin".
The search was limited to RCT studies conducted on
humans and English language articles.
Selection process
The initial selection process was realized independently
by 2 researchers. The title, abstract, and key words of iden-
tified studies were screened independently by both
reviewers for relevance.
No attempts were made at this time to identify studies that
did not use adequate control group, because it was consid-
ered improbable that abstracts would report enough
information about the setting. The subsequent selection
was made to identify only articles that dealt specifically
with the inclusion criteria.
Quality assessment
The methodological quality for the included studies was
assessed with a predetermined appraisal form, focusing
the following issues: bibliographic details, details of the
study setting as method of randomisation and blindness
of patients, therapist and examiners, characteristics of
study population, frequency and course of the interven-
tions, baseline and outcome measures, completeness of
follow-up.
Both reviewers independently assessed the quality of each
study. The strengths and weaknesses of the study design of
each included study were analysed. Disagreements on
validity assessment were resolved by consensus and dis-
cussion.
Results
The search identified 24 articles found in MEDLINE, 5
articles in EMBASE (already found in MEDLINE), 3 arti-
cles in Cochrane Central of Register Controlled Trials
(already found in MEDLINE).
The critical analysis of these 24 papers showed that:
1. all studies are published in English language.
2. three articles don't answer to the review question
because: in one the Authors try to outline a relationship
between Chlamydia Pneumoniae infection and patho-
genesis of increased gingival volume [34]; one study was
conducted on animals [35]; in the third one the Authors
suggest to treat CsA-induced gingival overgrowth admin-
istrating Tacrolimus, an alternative immunosuppressant,
instead of Cyclosporine [36].
3. five are letters to editor or short communications about
other previously published papers [37-41].
4. four are case reports [42-45].
5. one is a traditional review [46].BMC Oral Health 2008, 8:34 http://www.biomedcentral.com/1472-6831/8/34
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6. four are clinical trials [47-50].
7. two are controlled clinical trials (not randomised)
[51,52].
8. five are randomised controlled trials (RCTs) [53-57].
In this systematic review were included only 5 RCTs
excluding the remaining 19 studies.
Studies Design
These five studies were RCTs and subjects were kidney
transplant patients.
In the study published by Nash & Zaltzman [53], the effi-
cacy of Azithromycin was examined in a double blind ran-
domised crossover trial. 17 patients were randomised into
2 groups: one group received placebo for 5 days and after
2 weeks AZM (500 mg day 1, and 250 days 2–5) and the
other group received AZM before placebo. Outcome
measures were: gingival sulcus depths, tooth length and
length of interdental papilla to the CEJ of two teeth in
each of the four quadrants. The first group showed imme-
diate improvement for the three analyzed periodontal
parameters (pocket depth, tooth length, distance inter-
dental papilla-CEJ) after receiving AZM, the second group
had significant improvement immediately after AZM ther-
apy but 3 weeks after there was a deterioration of the GD
(gingival sulcus depth).
Besides the pharmacological therapy reduced the amount
of gum bleeding and 67% of the patients reported that the
treatment was at least somewhat useful.
In the study of Mesa et al. [54] 40 adult renal transplanted
patients were included in a double blinded controlled
randomised study. Patients were randomised into 3
groups (A: 13 subjects received MZN 250 mg 3 times for 7
days, B: 14 subjects received AZM 500 mg 2 times/die for
7 days, C: 13 received one cap of placebo 3 times daily for
7 days). Gingival and dental area were measured and the
relationship between them was considered the GO index.
The pretreatment GO index was 0.895 ± 0.16 for group A
and after 30 days GO index was 0.897 ± 0.28, for group B
was 0.932 ± 0.11 and after 30 days it became 0.909 ± 0.15,
for group C was 1.073 ± 0.32 and at the end was 1.130 ±
0.30. After 30 days none of the patients with GO showed
complete remission.
Morphometric index of GO, a particular kind of photo-
graphic analysis matching the gingival area and the tooth
area, didn't show an improvement after the proposed
pharmacological therapies; a 7-day course of Azytromicin
or Metronidazole or placebo didn't produce statistical sig-
nificative differences. Antibiotics seemed to act against
bacterial over-infection and concomitant gingival inflam-
mation.
In the study conducted by Nafar et al.[55] 25 patients were
randomised into 4 groups (group 1 received systemic
AZM on the first visit in the form of 6 caps, 2 on first day
and 1 per day for 4 consecutive days, group 2 received pla-
cebo in the same way of group 1, group 3 received local
AZM in form of oral gel for 1 week, group 4 received pla-
cebo in similar way to group 3).
Clinical parameters were bleeding on probing (BOP), GO
index and plaque length (PL). Biometric parameters were
probing pocket depth (PPD), crown length (CL) and stent
interdental papilla (IDP).
Only BOP index showed an improvement after 2 or 6
weeks of the 4 therapies performed. But during the first
visit all patients received a professional scaling and root
planing using ultrasonic cavitron after the administration
of 2 gr. of Amoxicillin: in this way local periodontal irrita-
tive deposits were removed. The other adopted periodon-
tal parameters didn't show significant differences.
In the study published by Chand et al. [56] 25 patients
(mean age of 17.48 years) were included in a double
blinded randomised study and divided into 2 groups: the
first one received AZM 500 mg on the first day and 250 mg
days 2–5, the other group received Metronidazole (MNZ)
45 mg/kg/die divided into 3 doses daily for 7 days. Base-
line gingival measurements were 12.87 ± 0.40 mm for
AZM group and 13.13 ± 0.29 mm for MNZ group. After 24
weeks gingival measurements were 11.50 ± 0.14 mm for
the first group and 12.23 ± 0.12 mm for the second. The
most significative difference was found at 4 weeks: at this
time Azytromicin group was significantly more effective
than Metronidazole.
In the study published by Ramalho et al. [57] 20 renal
transplanted patients with GO were enrolled and ran-
domised into two groups: group A received AZM 500 mg
for 3 days with oral hygiene program for 30 days, while
the control group received only the oral hygiene program.
Outcome measures were: subjective evaluation of oral
hygiene, Simplified Oral Hygiene Index (SOHI) [58] and
GH index [59].
About the first outcome measure patients in both groups
declared to have improved their dental condition, in fact
they had less pain and bleeding. For the other outcome
measures, after 15, 30 and 60 days patients in AZM group
showed statistically significant improvement of SOHI and
GH index.BMC Oral Health 2008, 8:34 http://www.biomedcentral.com/1472-6831/8/34
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In the data summary table 2 patients enrolled, therapy
administered, study location, study design, duration, out-
comes measures and results are available.
Discussion
Analysing the eligible studies it arose heterogeneity in var-
ious aspects of studies design such as patients characteris-
tics (mean age for example), timing of therapy and follow
up, kind of therapy put in comparison (AZM with MZM
or Placebo) and drug's daily dose. Also a relevant hetero-
geneity of diagnostic tools and outcome measures was
highlighted: in every study different parameters such as
pocket depth, bleeding on probing, plaque index, photo-
graphic analysis, interdental papilla height, tooth length
were used to evaluate the degree of GO. Evaluating the
results, the difficulty in pooling data from these selected
studies was evident: consequently it was impossible to
perform a meta-analysis with sensitivity analyses because
the multiple differences between them and their insuffi-
cient number impaired a statistical combination of data.
The only way to make sense of the different results from
the selected studies was the construction of a data sum-
mary table.
Anyway, AZM, only if associated with SRP, could be con-
sidered a better way to treat GO caused by CsA therapy
than MZM or placebo such as it arose considering these 5
eligible studies. In fact in the studies of Nash et al., Nafar
et al. and Chand et al. subjects treated with AZM associ-
ated with calculus and plaque removal had improvement
of their condition of GO with statistically significant
results. In the study of Ramalho et al. AZM associated with
oral hygiene program reduced GO. Only in Mesa et al.
Table 2: Studies characteristics
Study Chand DH et al. 
2004
Nafar M et al. 2003 Mesa FL et al. 2003 Nash et al. 1998 Ramalho et al. 
2007
Participants 25 (17 m, 8 f) mean 
age: 17.5 ± 6.06 ys
25 (16 m, 9 f) mean 
age: 40 ys 
(range 15–60)
40 (? m, ? f) mean age: 
41.4 ys (range 24–60)
17 (12 m, 5 f) mean 
age : none specified
20 (f) mean age: 32 ± 
3 ys
Setting Cleveland Clinic 
Found., Cincinnati 
Children's Medical 
Centre
2 medical centres in 
Teheran
University hospital of 
Granada
None specified University Ospital of 
Sao Jose do Rio Preto
Interventions A: AZM 500 mg day 
1, 250 mg. days 2–5
B: MNZ 45 mg/kg/die, 
3 doses daily for 7 
days.
(All, during the first 
visit: SRP + 2 g 
amoxicillin)
A: AZM 500 mg day 
1, 250 mg days 2–5
B: placebo for 5 days.
C:AZM gel 25% for 7 
days.
D: placebo for 7 days.
A: MNZ 250 mg 3 
times/die for 7 days.
B: AZM 500 mg 2 
times/die for 7 days.
C: placebo 3 times/die 
for 7 days.
A: placebo for 5 days 
+ (after 2 weeks) 
AZM 500 mg day 1, 
250 mg days 2–5
B: AZM 500 mg day 1, 
250 mg days 2–5 + 
(after 2 weeks) 
placebo for 5 days
A: oral hygiene 
program
B: oral hygiene 
program + AZM 500 
mg for 3 days
Study Design Double Blind RCT Double Blind RCT Double Blind RCT Double Blind RCT RCT
Length 24 weeks 6 weeks 4 weeks 12 weeks 30–60 days
Outcomes 
measures
Pocket Depth (mean), 
photographs
Bleeding on Probing, 
GO index, Plaque 
Length, Pocket Depth, 
crown length, stent 
interdental papilla
Morphometric GO 
index, serum 
creatinine and 
creatinine clearance
Pocket Depth, tooth 
length, length of the 
interdental papillae to 
the cementum enamel 
junction, 
questionnaire, 
photographs
Subjective evaluation 
of oral hygiene 
(questionnaire), SOHI, 
GH index
Results Baseline GO:
A: 12.87 +/- 0.40 mm
B:13.13 +/- 0.20 mm
After 24 weeks:
A: 11.50 +/- 0.14 mm
B: 12.23 +/- 0.12 mm
Significantly results 
only for BOP. 
Insignificant 
differences between 
drug and placebo 
groups for other 
parameters
Not statistically 
significant results
Significant 
improvement in all 3 
types of periodontal 
measurements after 
assumption of AZM
Significant 
improvement of SOHI 
and GH index in 
patients in AZM groupBMC Oral Health 2008, 8:34 http://www.biomedcentral.com/1472-6831/8/34
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study there were not significant differences using AZM
instead of MZM or placebo.
One of the most recent papers on this topic [52] (Argani
et al. 2006) was considered very interesting but it was not
eligible because it was lacking of randomisation and
blindness. In fact the Authors examined the efficacy of
local Azithromycin, in the form of toothpaste, against
cyclosporine-induced gingival overgrowth, reducing the
patients compliance and the adverse effects of a systemic
therapy.
A well-designed randomised multicentric clinical trial
would be recommendable to enlarge the sample so that
results could be generalized.
Anyway, the pathogenesis of GO as well as the mecha-
nism of action of AZM still remains unclear. The great het-
erogeneity of diagnostic data and results in our systematic
review is due to the lack in literature of complete RCTs on
the efficacy of systemic antibiotic therapy of GO, mainly
due to the absence of precise diagnostic methods and
tools and of an adequate classification aimed to deter-
mine a correct prognosis and an appropriate therapy for
GO.
Future projections
Future researches are needed to outline a correct classifica-
tion and to use universally accepted, unambiguous diag-
nostic parameters and an ideal study design like a RCT: in
this way it is possible to identify an efficacious GO man-
agement.
Conclusion
In literature there are few RCTs on the efficacy of systemic
antibiotic therapy of GO and it is mainly due to the
absence of precise diagnostic tools and of an adequate
classification aimed to determine a correct prognosis and
an appropriate therapy for GO. The pathogenesis of GO as
well as the mechanism of action of AZM still remains
unclear: future researches are needed.
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